US equities
|
MU
$1,040.23
▼-4.39%
NVDA
$230.22
▼-3.05%
SNDK
$1,610.81
▼-4.82%
AMD
$616.68
▼-4.52%
INTC
$106.28
▼-6.05%
SPCX
$162.23
▼-3.20%
META
$719.37
▼-0.27%
MSFT
$521.50
▼-1.56%
MU
$1,040.23
▼-4.39%
NVDA
$230.22
▼-3.05%
SNDK
$1,610.81
▼-4.82%
AMD
$616.68
▼-4.52%
INTC
$106.28
▼-6.05%
SPCX
$162.23
▼-3.20%
META
$719.37
▼-0.27%
MSFT
$521.50
▼-1.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lantern Pharma Inc. - Common Stock
(NQ:
LTRN
)
0.8420
-0.0680 (-7.47%)
Delayed Quote
Updated: 2:41 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lantern Pharma Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 15
Today 10:40 EDT
Via
Investor Brand Network
Topics
Artificial Intelligence
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Today 8:00 EDT
From
Lantern Pharma Inc.
Via
Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives Taiwan Approvals to Advance Phase 2 HARMONIC(TM) Trial
October 07, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
October 07, 2026
From
Lantern Pharma Inc.
Via
Business Wire
NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering
October 01, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
September 30, 2026
From
Lantern Pharma Inc.
Via
Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering
September 29, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
September 29, 2026
From
Lantern Pharma Inc.
Via
Business Wire
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
September 26, 2026
Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p.m. ET broadcast reaching audiences across the United States, Latin America and MENA
From
New to The Street
Via
ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar
September 23, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
September 23, 2026
From
Lantern Pharma Inc.
Via
Business Wire
MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent
September 22, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
September 22, 2026
From
Lantern Pharma Inc.
Via
Business Wire
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
September 19, 2026
BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient Needs
From
New to The Street
Via
ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap
September 17, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
September 17, 2026
From
Lantern Pharma Inc.
Via
Business Wire
New to The Street Show 771 Airs Today on Bloomberg, Featuring Bill Mobley, Panna Sharma, Phillip Toppino and Dr. Kelley Gurley
September 12, 2026
The program broadcasts at 6:30 p.m. ET across the United States, Latin America, MENA and Southeast Asia-supported by New to The Street's 6.3 million-plus YouTube subscriber ecosystem, second only to...
From
New to The Street
Via
ACCESS Newswire
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
September 05, 2026
October 3 Southeast Asia launch will add distribution reaching approximately 68 million households
From
New to The Street
Via
ACCESS Newswire
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
August 29, 2026
From
New to The Street
Via
ACCESS Newswire
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
↗
August 21, 2026
LP-300 shows strong efficacy in lung cancer while operating losses shrink 25%.
Via
The Motley Fool
Topics
Earnings
NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI
August 14, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
From
Lantern Pharma Inc.
Via
Business Wire
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
August 08, 2026
From
New to The Street
Via
ACCESS Newswire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Second-Quarter 2026 Results Webcast
August 07, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
August 07, 2026
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
August 03, 2026
From
Lantern Pharma Inc.
Via
Business Wire
New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial
August 01, 2026
From
New to The Street
Via
ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) EMA Clears LP-184 Bladder Cancer Trial in Europe
July 28, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
July 28, 2026
From
Lantern Pharma Inc.
Via
Business Wire
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings
July 25, 2026
From
New to The Street
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
